| INTRODUCTION
Asthma is a heterogeneous disease, which can be classified into various phenotypes according to clinical, inflammatory or physiologic characteristics, treatment responsiveness and prognostic factors. 1 The technique of induced sputum has allowed to define 2 inflammatory phenotypes: eosinophilic and non-eosinophilic asthma. 2 According to international guidelines, ICSs are the first-line controller treatment in asthmatic patients, 3 whichever their inflammatory phenotype. Non-eosinophilic asthmatics are, however, usually considered poorly responsive to ICS. 4 Several studies have indeed
shown that the effect of short-term treatment with ICS on symptoms, quality of life, baseline airway calibre and bronchial hyperresponsiveness was lower in non-eosinophilic asthmatics as compared with their eosinophilic counterparts. [5] [6] [7] [8] Whether these non-eosinophilic asthmatics are unresponsive, 5, 6 partly responsive 7, 8 or well responsive 9 to ICS is still controversial. This is, however, an important concern because they account for approximately 60% of corticosteroid-naive asthmatic patients when the threshold to define sputum eosinophilia is set at 3%. 10 In studies assessing the impact of discontinuing or reducing the dose of ICS in controlled asthmatics, increased sputum eosinophils at baseline 11, 12 or a raise in sputum eosinophils during the stepdown [13] [14] [15] was found to be predictive markers for asthma deterioration. These studies had, however, included both eosinophilic and non-eosinophilic patients. Nevertheless, it has been suggested that stepping-down ICS in eosinophilic asthmatics might put those patients at risk of exacerbations. 11 A step-down of ICS may, however, be acceptable in non-eosinophilic asthmatics, 16 but studies in this specific population are currently lacking.
The aims of our study were twofold. First, to assess the proportion of non-eosinophilic patients in whom ICS may be withdrawn without any degradation of asthma control and exacerbation rate and second, to determine the predictive markers of a failure to stop treatment with ICS.
2 | ME TH ODS were asthmatics aged of at least 18 years, had a sputum eosinophil count <3% combined with a blood eosinophil count <400/lL 17 and
| Setting and participants
were treated with ICS at the same dose since the previous 3 months. Patients were excluded if they had a history of near-fatal asthma requiring a stay in intensive care unit, if they were treated with oral corticosteroids (OCSs) at screening visit or had been treated with OCS in the previous 4 weeks, if they were treated with omalizumab or if they were pregnant women. The study was approved by the Ethics Committee of the University Hospital of Liege (Reference 2014/98) and registered with ClinicalTrials.gov, number NCT02169323. All patients gave written informed consent.
| Study design
The study was prospective, monocentric and interventional. The study design is shown in Figure 1 .
Before stepping-down ICS, an intermediate phase of treatment step-up was performed at the beginning of the study in patients whose asthma was uncontrolled despite a low or medium dose of ICS. In these asthmatics, the treatment was stepped-up to the GINA step 4 with a high dose of ICS for 3 months. This stage was included in the study design to ensure that each patient was treated in accordance with the international guidelines before stepping-down the ICS dose. This step-up phase also gave us the opportunity to study the impact of an increased dose of ICS in symptomatic non-eosinophilic asthmatics.
For all study patients, the intervention consisted of a progressive step-down of ICS every 3 months according to the dose levels defined by the GINA guidelines (from a high dose to a medium dose to a low dose to a complete cessation) until the patients met the failure criteria (see below) or discontinued ICS for 6 months. The visit preceding the first step-down was considered as the baseline visit. At each 3-month visit or whenever during the study on request by the patient, the ACQ score and the number of severe exacerbations were assessed to determine the pursuit of the study. This assessment was always performed outside an asthma exacerbation.
An ACQ score ≥1.5 with an increase from the baseline score by more than 0.5 point and/or a cumulated number of severe exacerbations from baseline greater than the number of severe exacerbations during the year prior to the baseline visit were deemed as failure criteria in the study. Patients meeting at least one of these criteria were therefore withdrawn from the study and were prescribed an adequate dose of ICS. Patients who did not meet the failure criteria continued the study protocol.
As described in Figure 1 , patients had a detailed investigation at study entry, at each 3-month visit and at the last visit. If patients had a severe exacerbation at any of these scheduled visits, the detailed investigation was postponed and performed at least 4 weeks after the last dose of OCS.
| Study investigations
Atopy was defined as the presence of 1 or more positive specific IgE (>0.35 kU/L) to at least one of the following aeroallergens: cat, dog, grass pollen, tree pollen, house dust mite and a mould mixture (Phadia, Groot-Bijgaarden, Belgium). Fractional exhaled nitric oxide (FENO) was measured at a flow rate of 50 mL/s (NIOX; Aerocrine, Solna, Sweden). Sputum induction and processing with the wholesample technique was performed as previously described. 18 The technician who performed the sputum cell count was blind to the clinical status of patients. Asthma control was assessed by the Asthma Control Test (ACT) 19 and Asthma Control Questionnaire (ACQ) 20 scores. Asthma-related quality of life was measured by the Mini Asthma Quality of Life Questionnaire (Mini-AQLQ) score. 21 The
Shortened version of the Inhaled Corticosteroids side-effect Questionnaire (ICQ-S) was used to monitor side-effects of ICS. 22 The ICQ-S score ranges from 0 (no side-effect) to 90 (highest levels of side-effects). 22 The adherence to ICS was measured by the 5-item Medication Adherence Report Scale (MARS-5) score. 23, 24 The MARS-5 score ranges from 5 (the worst) to 25 (the best adherence). 23 The inhalation technique for ICS was checked at each visit, and the number of errors was recorded. A severe exacerbation was defined as the use of systemic corticosteroids during at least 3 days or a hospitalization/emergency room visit due to asthma with use of systemic corticosteroids. 25 We recorded the number of severe exac- Step-down 3
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PaƟents with a high ICS dose at baseline F I G U R E 1 Schematic representation of the study design. ACQ, asthma control questionnaire; ACT, asthma control test; AQLQ, asthma quality of life questionnaire; FENO, fractional exhaled nitric oxide; ICQ-S, shortened version of the Inhaled corticosteroids side-effect questionnaire; ICS, inhaled corticosteroid; MARS-5, 5-item medication adherence report scale 
| RESULTS
A total of 312 asthmatic patients were assessed for eligibility, of whom 43 were included in the study and 36 completed the protocol ( Figure 2 ). From these patients, 14 were successfully weaned off ICS, while 22 patients failed to stop ICS. The median time of followup was 9 months (IQR: 5-13 months).
| Treatment step-up in uncontrolled patients
At study entry, 13 patients had an ACQ score ≥1.5 while not being treated with a high dose of ICS. Overall in these patients, a treatment step-up to the GINA step 4 with high-dose ICS did not result in any functional, clinical or inflammatory changes, apart from a reduction in FENO (P = .02, Table 1 ). We, however, noticed that 5 patients had a clinically significant improvement in asthma control after this treatment step-up (defined as a decrease in ACQ >0.5
and/or an increase in ACT >3). 
| Step-down of ICS
Demographic characteristics of all study patients are summarized in Table 2 . Functional, clinical, inflammatory and treatment characteristics at baseline, after the first step-down, and at the last visit in Table 3 .
At baseline, patients who subsequently failed to be weaned off ICS were older and had higher blood eosinophils than patients who successfully stopped ICS (P = .006 for both comparisons; Table 2 and Table 3 , respectively). 14 AE 4 vs 20 AE 4, P = .01), a higher baseline ACQ score (mean AE SD: 2.6 AE 0.9 vs 0.8 AE 0.8, P = .003), a lower baseline T A B L E 1 Patient characteristics and effect of treatment step-up in uncontrolled non-eosinophilic asthmatics treated with a low or medium dose of ICS at study entry Non-eosinophilic asthmatics with an ACQ ≥1.5 and treated with a low or medium dose of ICS at study entry (N = 13) patients whose asthma control did not improve when ICSs were stopped, it should be noted that 3 patients had sputum eosinophils ≥3% at least once during the study.
In patients who failed to stop ICS (N = 22), their last visit was associated with a worsening in FEV 1 , forced vital capacity (FVC), reversibility to salbutamol, ACQ, sputum eosinophils and blood fibrinogen as compared with baseline (Table 3 ). In those patients in whom a complete cessation of ICS was unsuccessful, a step-down to a reduced ICS dose was, however, possible without meeting the failure criteria in 10 patients (45%). In this subgroup, the ICS dose was reduced by a median (IQR) of 1000 (400-1600) lg beclomethasone CFC equivalents. It is also worth noting that all patients who had an improvement in asthma control after the treatment step-up and who completed the protocol failed to completely stop ICS.
When looking at the evolution of clinical and inflammatory outcomes throughout the study, the loss of asthma control was concomitant with increased blood and sputum eosinophils in patients who failed to stop of ICS, whereas these inflammatory parameters were rather stable over time in patients who successfully discontinued ICS (Figure 3) .
In a subgroup analysis, we assessed the success rate of ICS cessation according to the level of asthma control at baseline. In the subgroup of patients with an ACQ <1.5 at baseline, ICSs were successfully withdrawn in 40% of patients (8 of 20) , while the success rate was 38% (6 of 16) in the subgroup of patients with an ACQ ≥1.5 at baseline despite treatment with high-dose ICS.
We also analysed the success rate of ICS cessation according to the season at last visit of patients. The success rate was 50% (4 of 8) in patients whose last study visit was in summer, 45% (5 of 11) in patients with a last visit in spring, 14% (1 of 7) in patients with a last visit in autumn and 40% (4 of 10) in patients who finished the study in winter (P = .54 for the comparison).
| Predictors of a failure to stop ICS
ROC analyses for predictors of an unsuccessful withdrawal of ICS are presented in Table 4 . Predictors at baseline and after the first step-down correspond to the variables that were statistically different between the success and failure groups at these time-points. At baseline, a greater age and elevated blood eosinophils were found to be predictive of a failure to stop ICS (area under ROC curve: 0.77 for both predictors, Table 4 ). After the first step-down, an elevated number of blood eosinophils were the best predictor of an unsuccessful withdrawal of ICS (area under ROC curve: 0.85, Table 4 ). A subanalysis of the failure rate of ICS withdrawal according to several thresholds of blood eosinophils at baseline and after the first stepdown was also performed and is shown in Table 5 . To find individual predictors of a failure to stop ICS, we compared the absolute changes in the continuous variables of Table 3 from baseline to first step-down between both groups of patients. The variation in the ACQ score was the only variable that was statistically significant between both groups of patients, and its ability to predict an unsuccessful withdrawal of ICS is presented in Table 4 (area under ROC curve: 0.76).
In the subgroup of patients who had an ACQ ≥1.5 despite treatment with high-dose ICS before the step-down, predictors at baseline of a failure to stop ICS were a greater age and elevated blood eosinophils, while the only predictor after the first step-down was an elevated blood eosinophil count (Table 6 ).
| Adherence to ICS and inhalation technique
At each visit (except when patients were weaned off ICS), the adherence and inhalation technique were measured for ICS. Adherence to ICS was good in both groups at baseline (median MARS-5 (14) 2 (14) 3 (14) Ex-smokers 15 (42) 6 (43) 9 (41) BMI, body mass index; ICS, inhaled corticosteroid.
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ICQ-S [21] [22] [23] [24] [25] in the success group and 25 [23] [24] [25] in the failure group) and at subsequent visits (median MARS-5 score
[IQR]: 24 [23] [24] [25] in the success group and 25 [24] [25] in the failure group). The median (IQR) number of errors in the inhalation technique was 1 (0-2) for both groups at baseline and was 0 (0-1)
in the success group and 1 (0-1) in the failure group at subsequent visits.
| DISCUSSION
The importance of personalized medicine has been largely emphasized over recent years. Corticosteroid responsiveness in asthma is certainly a major issue in this regard. In corticosteroid-naive patients, the presence of eosinophilic airway inflammation seems necessary to have a good clinical response to ICS. Our study shows that stepping-down ICS in non-eosinophilic asthmatics is feasible in clinical practice irrespective of baseline asthma control. About one-third of the patients can be completely weaned off ICS while 1 further third can be stepped-down to a reduced ICS dose without compromising asthma control and exacerbation rate. In those patients who are getting uncontrolled when withdrawing ICS, it is of interest that blood eosinophil count may alert the clinician to the risk of asthma deterioration.
Although the major aim of our study was to investigate the stepdown of ICS in non-eosinophilic asthmatics, an intermediate phase of step-up was included in our protocol for those patients who were uncontrolled at study entry despite a treatment with a low or moderate dose ICS. While this step-up did not result in any overall clinical improvement when the whole subgroup was analysed, it is noteworthy that those individual patients with higher FENO levels had a clinically significant improvement in asthma control (defined as a decrease in ACQ >0.5 and/or an increase in ACT >3) 3 with an increased dose of ICS. These data are in keeping with several studies
showing that some steroid-naive non-eosinophilic patients might benefit from ICS, 8, 9, 26 particularly those with increased FENO levels. 8 It has been suggested that sputum [11] [12] [13] [14] [15] and blood 15 eosinophils may predict asthma deterioration following a decrease or withdrawal of ICS in well-controlled asthmatics. In non-eosinophilic patients defined by sputum eosinophils <3% and blood eosinophils <400/lL, our data show that elevated blood eosinophils at baseline and elevated blood or sputum eosinophils after the first step-down phase were predictive of a failure to withdraw ICS. As previously suggested, 27 a low-grade eosinophilic inflammation may therefore exist in non-eosinophilic asthmatics and may explain an unsuccessful withdrawal of ICS. As far as FENO is concerned, it did not predict a failure to stop ICS in our study, in accordance with previous findings. 13, 14 International guidelines recommend to step-down treatment once asthma control has been achieved for at least 3 months. 3 However, in keeping with studies tailoring asthma treatment according to sputum eosinophils, 16, 28 we chose to step-down ICS in non-eosinophilic asthmatics irrespective of baseline asthma control. It is therefore worth noting that one-third of uncontrolled asthmatics despite treatment with high-dose ICS at baseline were successfully weaned off ICS without any clinical degradation. Besides, monitoring sputum eosinophils during the step-down process is of importance because some patients may tolerate an increase in sputum eosinophils without any degradation in asthma control, as previously reported. 18, 29 In those patients, the ICS dose should be raised to reduce the risk of exacerbations associated with eosinophilic inflammation.
30,31
F I G U R E 3 ACQ score (A), absolute blood eosinophil count (B) and sputum eosinophil percentage (C) at baseline, after the first step-down and at the last visit in patients with a successful and unsuccessful withdrawal of ICS. Data are expressed as mean (SD) for ACQ and median (IQR) for blood and sputum eosinophils. | 533 study included both exacerbations and worsening in asthma control.
Moreover, in studies included in these meta-analyses, patients were selected based on a good asthma control but not according to their eosinophilic phenotype. However, we are convinced that the stepdown approach in these studies would have been more effective if sputum eosinophils had been taken into account.
Remarkably, in our study, an improvement in asthma control and a reduction in exacerbation rate were observed in patients who were successfully weaned off ICS. The reasons for this improvement are unclear, but one can hypothesize that local side-effects and reduced local immunity with ICS might play a role. Although withdrawing ICS was not possible in 60% of the study population, a reduction in the ICS dose was feasible in half of these patients without clinical degradation over a 3-month period. In clinical practice, the importance to find the lowest effective treatment with ICS is explained by the fact that high-dose ICSs are associated with local and systemic sideeffects, 35, 36 increased risk of respiratory infections 37, 38 and costs.
A strength of our study is that there are currently little data in the literature on ICS step-down in non-eosinophilic asthmatics.
Moreover, the time of follow-up was reasonably long in our protocol, with step-down phases every 3 months and an observation time of patients without ICS of 6 months.
Our study has some limitations. First, non-eosinophilic asthmatics were defined based on a single measurement of sputum and blood eosinophils at baseline. Therefore, we cannot exclude that a part of the study patients had intermittently eosinophilic asthma, a phenotype known to partly respond to corticosteroids. 39 Second, because all patients defined as non-eosinophilic at study entry were treated with ICS when sputum and blood were sampled, we acknowledge that a part of our study population was probably misclassified as non-eosinophilic. This was confirmed by the fact that some patients showed a recrudescence of eosinophilic inflammation when ICSs were stepped-down. A way to correctly assess the inflammatory phenotype of patients would have been to measure sputum and blood eosinophils during a steroid withdrawal step at study entry, but this was impracticable in a real-life clinical trial. Third, our study had no control group, which means that we could not compare our results with those obtained in a group of patients who were kept on a stable dose of ICS. Fourth, our study was not blinded and we may hypothesize that the failure rate would have been lower in a blinded study, which may be explained by the presence of some patients anxious to be deprived of a chronic treatment supposed to be essential for controlling their disease. Fifth, our study was not powered to assess the impact of seasonal changes on the success rate of the stepdown process, but we can hypothesize that such changes might contribute to the failure to stop ICS in some patients. Finally, as it was a monocentric study, the number of included patients was quite limited, despite a fair number of screened patients.
In conclusion, our data provide evidence that stopping or reducing the dose of ICS may be possible irrespective of baseline asthma control in a substantial part of non-eosinophilic asthmatics without compromising asthma control and the risk of exacerbations. This finding, which challenges the current international recommendations, urgently needs to be confirmed in large prospective multicentre randomized controlled trials. 
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